Breast: Breast RT technique (cardiac sparing, DIBH)
Free question published 17 November 2026
A 46-year-old woman is to receive adjuvant whole-breast radiotherapy for a left-sided, node-negative invasive carcinoma after breast-conserving surgery. The planning team is considering a deep inspiration breath-hold (DIBH) technique. A trainee asks why cardiac dose matters. Which statement best describes the relationship between mean heart dose and ischaemic heart disease, and the rationale for DIBH?
- AMajor coronary events increase linearly with mean heart dose, with no apparent threshold, so DIBH is used to lower heart dose
- BCardiac events occur only decades later, so DIBH offers no meaningful benefit
- CThere is a safe threshold below 5 Gy with no excess risk, so DIBH is unnecessary
- DDIBH increases mean heart dose but improves target coverage
- ECardiac risk only rises above 30 Gy mean heart dose
Why A is correct
The Darby population-based case-control study showed the rate of major coronary events increased linearly with the mean radiation dose to the heart, with the increase beginning within the first few years and persisting, and with no apparent threshold. Because risk is proportional to whole-heart dose with no known threshold, cardiac-sparing techniques such as deep inspiration breath-hold are used to reduce mean heart dose during left-breast radiotherapy.
And why the others are not
- BIncorrect. The increased risk began within the first few years after radiotherapy, not only decades later.
- CIncorrect. The study found no safe threshold; risk increased even at low mean heart doses.
- DIncorrect. DIBH lowers, not raises, mean heart dose by moving the heart away from the chest wall during inspiration.
- EIncorrect. The relationship is linear from low doses, not confined to doses above 30 Gy.
Source Darby et al - risk of ischaemic heart disease after breast radiotherapy — Darby SC, Ewertz M, McGale P, et al. Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer. N Engl J Med. 2013;368(11):987-998.
More free breast questions
- Breast: Metastatic HR-positive CDK4/6 · 06 November 2026
- Breast: Adjuvant chemotherapy and genomic assays · 26 October 2026
- Breast: Adjuvant endocrine therapy (ovarian suppression) · 15 October 2026
Sitting in February? Follow the twenty-week plan.
2,500+ cited questions like this one are waiting in the vault.
See plans and pricing